Key result
Anti-TNFa therapy and disease remission were associated with aortic destiffening in patients with inflammatory bowel disease, whereas aPWV increased in those with active disease (P=0.01).
Why the study?
To test whether chronic inflammation explains increased aortic pulse-wave velocity in inflammatory bowel disease and whether anti-TNFa therapy reduces it.
Does anti-TNFa therapy reduce aortic pulse-wave velocity in patients with inflammatory bowel disease?
Population
334 participants (82 ulcerative colitis, 85 Crohn disease, and 167 matched healthy controls)
Comparison
Patients with IBD vs healthy controls, and anti-TNFa therapy vs other disease/treatment statuses
Design
Multicenter longitudinal study
Follow-up
4 years (range, 2.5-5.7 years)
Authors
Loading...
Chronic inflammation may underlie arterial stiffness in IBD; leaves open whether anti-TNFα therapy reduces excess CV risk.
Cohort (n=334)
Yes
Does anti-TNFa therapy reduce aortic pulse-wave velocity in patients with inflammatory bowel disease?
p-value: p=0.01
Long-term anti-TNFa therapy reduces aortic pulse-wave velocity in patients with inflammatory bowel disease, suggesting that effective control of inflammation may reduce cardiovascular risk.
Zanoli et al. (2019) conducted a cohort in Inflammatory bowel disease (n=334). anti-TNFa therapy vs. salicylates or active disease was evaluated on change in aortic pulse-wave velocity (aPWV) (p=0.01). Anti-TNFa therapy and disease remission were associated with aortic destiffening in patients with inflammatory bowel disease, whereas aPWV increased in those with active disease (P=0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: